FDA Brief

Warning letters Food

FDA warning letter to

Holographic Health, Inc.

High riskIssued Sep 10, 2021Posted Sep 28, 2021Division of Human and Animal Food Operations East V

FDA says Holographic Health marketed 14 products as unapproved new drugs through disease claims on its website.

What happened

FDA reviewed www.holographichealth.com and found the company took orders for 14 products whose website claims said they treat or prevent diseases and affect body structure or function. FDA said the products are unapproved new drugs and misbranded because their labeling lacks adequate directions for use. FDA also said Pink Lady is marketed for topical use but labeled as a dietary supplement, which does not meet the dietary supplement definition.

What FDA found

  1. Website claims establish that the products are intended as drugs to treat or prevent disease and/or affect body structure or function.

    FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]
  2. The products are new drugs without FDA-approved applications.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product labeling lacks adequate directions for a layperson to use the drugs safely for their intended purposes.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5, 201.100(c)(2), 201.115
  4. Pink Lady is marketed for topical use but labeled as a dietary supplement, which only applies to products intended solely for ingestion.

    FD&C Act section 201(ff)(2)(A)(i) [21 U.S.C. 321(ff)(2)(A)(i)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, including related documentation. If corrective actions cannot be completed in that time, the company must state the reason and expected completion time.

Who should pay attention

  • online sellers and retailers of supplement-type products
  • dietary supplement brands that make disease claims
  • makers of eye, ear, or topical products sold as supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk